Raju Kapoor

Summary

Affiliation: University College London
Country: UK

Publications

  1. ncbi Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine
    Raju Kapoor
    National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N3BG, UK
    J Neurol Sci 274:54-6. 2008
  2. ncbi Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial
    Raju Kapoor
    Department of Neuroinflammation, National Hospital for Neurology and Neurosurgery and the Institute of Neurology, Queen Square, London, UK
    Lancet Neurol 9:681-8. 2010
  3. ncbi Axonal protection achieved in a model of multiple sclerosis using lamotrigine
    David A Bechtold
    Department of Clinical Neuroscience, King's College London, Guy's Campus, National Hospital for Neurology and Neurosurgery, London, UK
    J Neurol 253:1542-51. 2006
  4. ncbi Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design
    Raju Kapoor
    National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    Curr Opin Neurol 19:255-9. 2006

Collaborators

  • David H Miller
  • David A Bechtold
  • Yue Sun
  • Kenneth J Smith
  • Angela C Dawson
  • Sandra J Miller
  • David Berry

Detail Information

Publications4

  1. ncbi Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine
    Raju Kapoor
    National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N3BG, UK
    J Neurol Sci 274:54-6. 2008
    ..Clinical trials of neuroprotection using blockers of sodium channels are now under way. There is no agreement yet on several aspects of trial design, but the situation should become clearer once the results of these trials are reported...
  2. ncbi Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial
    Raju Kapoor
    Department of Neuroinflammation, National Hospital for Neurology and Neurosurgery and the Institute of Neurology, Queen Square, London, UK
    Lancet Neurol 9:681-8. 2010
    ..In this phase 2 trial, we aimed to assess whether the sodium-channel blocker lamotrigine is also neuroprotective in patients with secondary progressive multiple sclerosis...
  3. ncbi Axonal protection achieved in a model of multiple sclerosis using lamotrigine
    David A Bechtold
    Department of Clinical Neuroscience, King's College London, Guy's Campus, National Hospital for Neurology and Neurosurgery, London, UK
    J Neurol 253:1542-51. 2006
    ..5 %+/-38.5; lamotrigine: 10.4 %+/-12.5, P<0.01). The findings suggest that lamotrigine may provide a novel avenue for axonal protection in MS...
  4. ncbi Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design
    Raju Kapoor
    National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    Curr Opin Neurol 19:255-9. 2006
    ..This review considers the rationale for different therapeutic strategies for neuroprotection and discusses the controversies of trial design...